Understanding GlaxoSmithKline's Trelegy Ellipta (NYSE:GSK) | Seeking Alpha
The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study | npj Primary Care Respiratory Medicine
Toby Capstick on X: "#Trelegy Ellipta: The second ICS/LAMA/LABA inhaler in the UK, licensed for #COPD. https://t.co/NSYtv7bTYS (An alternative ICS/LABA /LAMA inhaler is available: #Trimbow MDI) https://t.co/vQBgh9lvM2" / X
Per la terapia della BPCO vale la regola del “tre in uno” | GSK in Italia
FDA duyệt Trelegy (GSK), sau kết quả khả quan so sánh với combo 2 hoạt chất
Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study | Archivos de Bronconeumología
Jacob Plieth on X: "More on asthma. Interesting development - first time $NVS has disclosed LAMA/LABA/ICS triple $GSK $AZN $THRX http://t.co/0bAiw6Qbfa" / X
IMPACT Study Data | TRELEGY ELLIPTA (fluticasone furoate, umeclidinium & vilanterol)
Hoitopolut
Pharmaceuticals | Free Full-Text | Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study - ScienceDirect
BPCO, cambia l'approccio. Due broncodilatatori la nuova terapia standard | AZ Salute
Contents Agenda Presenter biographies Presentations - ppt download
Population-based study of LAMA monotherapy effectiveness compared with LABA/ LAMA as initial treatment for COPD in primary care | npj Primary Care Respiratory Medicine
Proven mechanisms of action leading to synergistic or additive... | Download Scientific Diagram
Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine
Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study - ScienceDirect
ICS/LABA/LAMA per la BPCO è stata approvata in Europa • NCF
How Will The New GSK Respiratory Portfolio Fare In 2017? (NYSE:GSK) | Seeking Alpha
JCM | Free Full-Text | LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
Mario Cazzola, ERS 2018 – Impact of ICS/LABA and LABA/LAMA on lung function and exacerbation of COPD - YouTube
Farmacoutilizzazione della terapia inalatoria nella Medicina Generale italiana
LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the d | COPD
American College of Chest Physicians - In a real-world setting, LAMA-LABA- ICS is as effective as LAMA-LABA to prevent COPD exacerbations, but incidence of pneumonia increased with triple therapy initiation: https://hubs.ly/H0pPLQ20 | Facebook
that have recently been approved in some countries or are currently... | Download Scientific Diagram
